Who to call at Ocugen, and when
Fundz watches for the moments Ocugen starts buying, and tells you who to reach.
- An alert the day Ocugen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ocugen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ocugen. With Fundz connected, it knows.
Contract Type
licensing
MalvernBiotechnologyHealthcareHealth CareTherapeuticsDescription
Ocugen, Inc. has entered into an Exclusive License Agreement with Celairis Therapeutics Holdings Pty Ltd, granting Celairis exclusive rights to commercialize the OCU400 product in select countries across Asia and Oceania. The agreement includes a potential $6.1 million in fees and milestone payments, as well as royalties on net sales. The partnership aims to leverage Celairis's regulatory expertise to facilitate product approval and commercialization in the defined territory.
Quick answer
Ocugen Enters Exclusive License Agreement with Celairis Therapeutics (November 10, 2026). Ocugen is based in Malvern, Pennsylvania, United States.
- What agreement did Ocugen announce on November 10, 2026?
- Ocugen, Inc. has entered into an Exclusive License Agreement with Celairis Therapeutics Holdings Pty Ltd, granting Celairis exclusive rights to commercialize the OCU400 product in select countries across Asia and Oceania. The agreement includes a potential $6.1 million in fees and milestone payments, as well as royalties on net sales.
- What does Ocugen do?
- Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe.
- Where is Ocugen based?
- Ocugen is based in Malvern, Pennsylvania, United States.
- Which similar companies announced agreements around the same time?
- AbbVie Inc. (November 3, 2026), Aarvik Therapeutics (November 3, 2026), Cognito Therapeutics (October 27, 2026) and Sino Biopharmaceutical (November 13, 2026) also announced agreements within 45 days of Ocugen.
Source: Fundz verified event record.
Other recent agreements in Healthcare and Therapeutics
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Aarvik Therapeutics Enters Partnership with Laurus Labs for MUTTA™ ADC Development in India. (November 3, 2026)
- Rhode Island Life Science Hub and Cognito Therapeutics launch partnership for Alzheimer's research. (October 27, 2026)
- Sino Biopharmaceutical Partners with Boehringer Ingelheim in a $358 Million Oncology Deal (November 13, 2026)
- Pfizer Partners with Blackstone Life Sciences to Co-Fund $1.5 Billion Development for Berobenatide Obesity Drug. (November 14, 2026)
- Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment. (November 5, 2026)
Related People
Ocugen signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.